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Low back pain is exceptionally ubiquitous, complex, and costly. Nevertheless, lumbar 
spinal stenosis (LSS) with neurogenic intermittent claudication (NIC) is a frequent cause 
of low back and lower extremity pain. Although the phenomena and pathophisiology 
of lumbar spinal stenosis has been described for decades, therapeutic treatment 
options remain considerably limited. 
Current care consists of conservative measures including physical therapy, rest, 
medications, and epidural steroid injection therapy or invasive surgical treatment 
including laminectomy with or without fusion. Despite standard of care intervention, 
many patients are often left inadequately treated and suffer from debilitating low back 
and lower extremity pain as a result of lumbar spinal stenosis. Interspinous process 
distraction (IPD) devices were originally described in the 1950s, but technological 
advances, which have contributed to improved safety and efficacy, have rekindled an 
interest in IPD implantation. By mimicking lumbar flexion at affected levels of stenosis, 
it is thought these devices decompress neural structures within the neural foramina 
and therefore provide pain relief. X-STOP is one such device that is currently approved 
in the United States for the treatment of mild to moderate NIC resulting from LSS. 
This manuscript presents a focused review of NIC and LSS and comprehensively 
presents literature related to the use of the X-STOP IPD device. 
Key words: Interspinous process distraction (IPD), X STOP, interspinous spacer (ISS), 
lumbar spinal stenosis (LSS), neurogenic intermittent claudication (NIC), low back 
pain, sciatica
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Low back pain is extremely common today. The total costs of low back pain in the United States exceed $100 billion per year (1,2). In 1990 low 
back pain ranked as the fifth most common reason for 
all physician visits with nearly 15 million office visits 
that year (3). Furthermore, a review of the National 
Ambulatory Medical Care Survey for the years 1989 and 
1990 revealed that almost 4% of recorded diagnoses 
for low back pain were spinal stenosis (3). Evaluation of 
Medicare Physician Part B claims showed that in 2001 
over 2,000 lumbar epidural steroid injections were 
performed per 100,000 patients and that Medicare 
expenditures for all lumbosacral injections were over 
$175 million (4). Further, 23% of these injections 
were coded for spinal stenosis. Manchikanti et al (5,6) 
showed that lumbar radiculitis, disc displacement, 
spinal stenosis, and sciatica accounted for 53% of 
all epidural injections in 2002 and 54% in 2006. 
Therapeutic options for patients suffering from 
neurogenic intermittent claudication (NIC) secondary 
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nous nucleus pulposus encased in a rigid annulus fibro-
sis. The pars interarticularis is a region of the lamina 
bordered by the superior and inferior articular process-
es. These articular processes form the zygoapophyseal 
joints. It is the zygoapophyseal, or facet, joints that al-
low for lumbar stability during flexion, extension and 
lateral rotation of the spine. The spinous processes are 
afforded further stability by a dense interspinous liga-
ment and a dorsally bordered supraspinous ligament.
CliniCal Presentation, PathoPhysiology, 
and diagnosis of niC seCondary to lss
Verbiest has frequently been credited as first de-
scribing the clinical symptoms of posture related NIC 
secondary to LSS. In 1954 he published a series of 7 case 
reports of patients complaining of NIC caused by LSS 
(25). He noted that those patients developed radicular 
lower extremity pain, often bilaterally, on walking and 
standing that was relieved immediately with recum-
bency. In each case, myelography showed a block in the 
lumbar region, which was confirmed at operation (25). 
Verbiest also noted that on laminectomies of middle-
aged men with characteristic lower extremity radicular 
pain, the diameter of the lumbar spine was less than 
that of normal variants (25,26). 
The pathophysiology of LSS has been well de-
scribed by Kirkaldy-Willis and colleagues (27). Their in-
vestigations were based on dissection of 50 cadaveric 
lumbar spines and observations made during laminec-
tomies of 161 patients. They noted that as part of the 
degenerative process, lumbar spinal stenosis begins 
with repetitive minor trauma over many years. Like-
wise, presentation is most common upon or after the 
fifth or sixth decades of life. Ultimately, LSS is the result 
of destruction of the posterior joints causing synovial 
reaction, cartilage destruction, osteophyte formation, 
and intervertebral disc disruption. These changes ulti-
mately lead to loss of disc height and facet instability 
often accompanied by buckling of the ligamentum fla-
vum. As a result, the neural foramina and spinal canal 
are narrowed, impinging upon the structures within 
them, including the spinal cord, nerve roots, and cauda 
equina.
Although there is no universally accepted gold 
standard in the diagnosis of NIC caused by LSS, there 
are a number of clinical and diagnostic tools that aid 
in its identification. Unfortunately, findings from radio-
graphic modalities such as magnetic resonance imaging 
(MRI) and computed tomography (CT) poorly correlate 
with clinical symptoms (28). Likewise, this can make 
to lumbar spinal stenosis (LSS) are relatively limited. The 
options have conventionally consisted primarily of either 
conservative management including physical therapy, 
rest, analgesic or anti-inflammatory medications, and 
epidural steroid injections or surgical management 
including laminectomy with or without fusion (7-24). 
A relatively new device, however, may provide a 
third option for patients with symptomatic LSS. Origi-
nally available in Europe in June 2002, the X STOP device 
(Kyphon Inc., Sunnyvale, CA) is an interspinous process 
implant that was approved for clinical use in the United 
States by the Food and Drug Administration in Novem-
ber of 2005. Its approved indication is for the treatment 
of mild to moderate NIC resulting from LSS. This device 
is based on the observation that LSS with resultant NIC 
is often relieved when patients bend forward, and ac-
cordingly flex their lumbar spine. Upon this premise, 
the device is designed to fit between the spinous pro-
cesses at the stenotic lumbar level thereby mimicking 
lumbar flexion and limiting extension at the localized 
level. Reportedly, this then widens the neural foramina 
and decompresses problematic neural structures. 
Although interspinous process distraction was 
originally developed in the 1950s, it was all but aban-
doned secondary to device dislodgement, poor clinical 
indication, and hardware malfunction. While a number 
of interspinous process distraction devices, or IPD de-
vices, have been developed, this paper aims to specifi-
cally examine the X STOP device, as it is currently the 
only FDA-approved IPD device available in the United 
States. We will highlight the pathophysiology and clini-
cal presentation of NIC caused by LSS and then compre-
hensively review the literature regarding X STOP utility 
and effectiveness. 
anatomy of the sPine
Composed of 24 vertebrae and the sacrum, the 
spine is both a durable structure and exquisitely flex-
ible, allowing for motion along a number of axes. Spe-
cifically, the lumbar spine is comprised of 5 vertebrae 
arranged in a lordotic fashion. Each vertebral body is 
represented by a cancellous core surrounded by a dense 
cortical rim. Projecting posteriorly at each level is the 
vertebral arch. From each vertebral arch projects the 
transverse processes laterally and the spinous process 
posteriorly. The pedicles, along with the lamina, form 
the lateral and posterior borders of the spinal canal. 
Connecting the lamina superiorly and inferiorly is the 
ligamentum flavum. The vertebral bodies are separated 
at each level via intervertebral discs made of a gelati-
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concrete diagnosis of LSS challenging and LSS might 
be easily unrecognized or misdiagnosed by practitio-
ners. Upon expert evaluation of 468 cases of patients 
aged 20 years or older who presented with primary 
symptoms of pain or numbness in the legs, Konno et 
al (29) found the overall prevalence of LSS was 47.4%. 
Other diagnoses from this study included lumbar disc 
herniation (17.7%), diabetic neuropathy (2.8%) and 
peripheral artery disease (8.3%). Furthermore, in spite 
of specialist evaluation and diagnostic studies, almost 
one in 4 patients was left with no other diagnosis than 
“not LSS.” In an attempt to develop a clinical diagnosis 
tool to identify patients with LSS, they determined that 
characteristics associated with LSS include age greater 
than 60, absence of diabetes, intermittent claudication, 
exacerbation of symptoms when standing up with im-
provement upon bending forward, symptoms with lum-
bar extension, good peripheral artery circulation, and 
an abnormal Achilles reflex. Correlating negatively with 
a diagnosis of LSS included a positive straight leg raise 
test and symptoms induced with lumbar flexion (29).
X stoP indiCations, ContraindiCations 
and PlaCement
The idea of restricting motion in the plane that pro-
duces pain, or so-called dynamic stabilization, is not a 
new concept. In a paper by Bono (30), he mentions that 
Dr. Fred L. Knowles is often recognized as pioneering 
interspinous process devices in the 1950s (30). Yet, long-
term use of this device was rare as it often became dis-
lodged, which necessitated its removal. Since that time 
a number of new devices have been developed on the 
premise of dynamic stabilization with a wide variety of 
suggested clinical indications. This paper, however, will 
focus on the FDA approved X STOP interspinous process 
device. The X STOP device is an all titanium metal, and 
therefore radiopaque, device. It consists of an oval tita-
nium core that is designed to fit within the interspinous 
ligament. It is secured within the ligament by 2 lateral 
wings. 
The device is indicated for use in patients aged 50 
years or older who are experiencing moderately im-
paired physical function secondary to NIC as a result of 
LSS. The X STOP may be implanted at one or 2 stenotic 
lumbar levels. Most importantly, candidates for place-
ment must report alleviation of claudication with lum-
bar flexion, with or without back pain, and have under-
gone at least 6 months of failed non-surgical treatment 
(31). Contraindications to placement of the X STOP de-
vice include:
1. allergy to titanium
2. spinal anatomy or disease that would prevent im-
plantation or cause instability
3. cauda equina syndrome 
4. severe osteoporosis
5. active systemic infection or localized infection at the 
site of implantation.
Placement of the X STOP device has been well 
documented by Zucherman et al (32). It is typically per-
formed under local anesthetic with the patient in the 
right lateral decubitus position. Patients are required 
to maintain a flexed position in order to aid in distrac-
tion of the spinous processes and facilitate device place-
ment. Surgical levels are first correctly identified with 
fluoroscopy. A 4 to 5 centimeter mid-saggital incision 
is then made over the appropriate spinous processes. 
The soft tissue is dissected to the fascia at which point 
the fascia is incised longitudinally to the right and left 
of midline. Great care is taken to maintain the integ-
rity of the supraspinous ligament. A curved dilator is 
then advanced through the interspinous ligament at 
its most anterior margin. The appropriate surgical level 
is then re-verified with fluoroscopy. The small dilator 
is removed and a larger dilator is placed. The larger 
dilator is then removed and a sizing distractor is placed 
with the patient maintaining spinal flexion. The spinous 
processes are then distracted until the supraspinous lig-
ament becomes taut. The proper X STOP implant size 
is then determined by an indicator on the distraction 
instrument. The distractor is removed and the X STOP 
device of indicated size is placed through the interspi-
nous process until the right lateral wing rests against 
the right side of the spinous processes. At this point, 
the left lateral wing is attached and fastened securely 
against the left side of the spinous processes with the 2 
wings approximated at midline. Proper positioning of 
the X STOP device is verified with anteroposterior and 
lateral fluoroscopy prior to closure. Procedural time 
is generally less than one hour and blood loss is usu-
ally less than 100 mL. Patients are typically discharged 
home within 24 hours of surgery with many patients 
returning home on the same day as surgery.
Validity of X stoP meChanism of 
aCtion
IPDs including X STOP have been reported to be ef-
fective in relieving low back pain and lower extremity 
radicular pain in appropriately selected patients with 
disc height loss and significant pain relief during flex-
ion (33). The mechanism of X STOP for pain relief is 
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still under investigation. Theoretically, X STOP implan-
tation supports the diseased lumbar spine segments in 
a more flexed position, but close to neutral alignment; 
it also reduces pathological mobility. Potential mecha-
nisms of pain relief include widening the lumbar spinal 
canal, diminishing neuroforaminal narrowing, reduc-
ing facet loads at implanted levels, decreasing intradis-
cal pressure, and increasing anterior and posterior disc 
heights. 
As mentioned above, the X STOP device is designed 
to distract the interspinous processes and limit exten-
sion at the affected level(s). In doing so, the neural 
foramina are allegedly spread and maintained open, 
decompressing neural elements and relieving claudica-
tion. Lee et al (34) was the first to report changes in 
neural canal and foramen dimensions following the 
placement of the X STOP interspinous device. Ten pa-
tients had 11 X STOP devices placed and were evaluated 
using MRI both pre- and post-operatively. From their 
study, they note that the mean dural sac area increased 
by 23% (73.6 vs. 90.2 mm²) after X STOP placement. In-
tervertebral foraminal area also improved by 36% (60.3 
vs. 82.3 mm²) with the X STOP device. In another study, 
Richards et al (35) examined 8 cadaveric lumbar spines 
from L2-L5. These cadaveric spines were cemented in 
a stabilizing brace and neural foraminal measurements 
were made at 15 degrees of flexion and extension with 
and without X STOP implantation. While maintained in 
extension with the interspinous device, the mean canal 
area increased by 18% (273 vs. 231 mm²) with canal di-
ameter increasing 10% (19.5 vs. 17.8 mm). Subarticular 
diameter of the implanted spines was 48% greater (3.7 
vs. 2.5 mm). Foraminal area increased 25% (106 vs. 133 
mm²) and foraminal width was 41% greater (3.4 vs. 4.8 
mm) among implanted specimens.
On in vivo examination, Siddiqui and colleagues 
(36) compared 6-month pre- and 6-month post-X STOP 
implantation lumbar MRI dimensions. This study in-
cluded 12 patients who underwent implantation at a 
total of 17 levels. In lumbar extension, left exit foramen 
dimensions increased by 34% (77.25 vs. 103.73 mm²) 
and right exit foramen dimensions increased 25.4% 
(90.67 vs 113.7 mm2). On spinal cross section examina-
tion of standing patients the mean canal dimension 
increased 20% (77.78 vs. 93.39 mm²), 16% in neutral 
(93.17 vs. 108.29 mm²) and 27% in extension (84.56 vs. 
107.35 mm²) with X STOP implantation. Furthermore, 
no change in overall lumbar posture was observed (36). 
This suggests that while placement of the X STOP device 
changes localized vertebral dimensions at implanted 
level(s), the overall lordotic orientation of the lumbar 
spine might be unaffected. Siddiqui et al (37) later ex-
amined 26 patients undergoing implantation of X STOP 
at a total of 15 single levels and 11 double levels for LSS 
with NIC. They again noted significant improvement in 
spinal canal dimension and the neural foraminal area 
after implantation.
Although these studies agree with the mechanis-
tic fundamentals of interspinous technology, they are 
limited in number and evaluate dimensions at a maxi-
mum of 6 months postoperatively. It is difficult to say 
whether these measured improvements in canal and 
foraminal area will be maintained over the long-term. 
Furthermore, the clinical significance of these changes 
in spinal and foraminal dimensions is uncertain.
Previous studies have shown that spinal fusion 
can result in instability at adjacent levels and that this 
abnormal motion might accelerate adjacent segment 
degeneration (34). In order to study lumbar kinemat-
ics after X STOP placement, Lindsey et al (38) examined 
7 cadaveric lumbar spines from L2-L5. The X STOP de-
vice was implanted at the L2-3 level and 2 CCD cameras 
were used to record the angle of implanted steel pins in 
flexion-extension, lateral bending, and axial rotation. 
As discussed, the X STOP device is designed to limit ex-
tension at implanted levels. Accordingly, flexion-exten-
sion range of motion at the implanted level was signifi-
cantly reduced in this study. Axial rotation and lateral 
bending at the implanted level, however, were not sig-
nificantly affected. Furthermore, with the exception 
of a decreased L4-L5 neutral to extension position, the 
kinematics of the adjacent levels was not significantly 
altered. This study also showed an overall decrease in 
flexion to extension range of motion for the entire lum-
bar specimen (Non-implant 25.8° vs. Implanted 20.8°) 
and a 2° decrease in L2-L5 lordosis.
X STOP device implantation effects on in vivo sagit-
tal kinematics was later studied by Siddiqui et al (39). 
Pre-operative and 6 month post-operative MRIs were 
obtained on 26 patients who had a total of 15 single 
level and 11 double level X STOP implantations. In or-
der to quantify the kinematic effect of X STOP implan-
tation, height, endplate angles, segmental and lumbar 
range of motion, and L1S1 angle were recorded. In this 
study, the X STOP device did not affect lumbar spine 
sagittal kinematics.  
It has also been argued that X STOP implantation 
might offset compressive forces at the localized level 
and in doing so increase facet joint pressure at adjacent 
levels. As a result of a potentially increased burden at 
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adjacent lumbar levels, this could conceivably acceler-
ate or promote degeneration. Wiseman et al (40) ex-
amined 7 cadaveric lumbar spines loaded with 700 N of 
compression in 15 Nm of extension. Pressure-sensitive 
film was inserted into the facet joints at the X STOP im-
planted level (L2-L3 level in all specimens) and adjacent 
levels. At the implanted level peak pressure of the facet 
joint was reduced 55% (3.73 MPa vs. 1.68 MPa), mean 
pressure decreased by 39% (0.93 MPa vs. 0.57 MPa), con-
tact area was reduced 46% (0.79 cm² vs. 0.42 cm²), and 
the mean force was reduced by 67% (83.2N vs. 26.8N) 
(40). The results, however, did not reveal a significant 
change in facet loading measurements at adjacent lev-
els. Although these are encouraging results, the affects 
of loading pressures in vivo remain to be investigated. 
Lazoro et al (41) examined the kinematics on the 
L1-2 segment before and after implantation with a 
novel minimally invasive lumbar interspinous spacer 
(Synthes USA, LLC, West Chester, PA) in 7 human cadav-
eric specimens. With interspinous spacer (ISS) in place, 
the range of motion and stiff zone during extension 
were significantly improved with less reduced forami-
nal height. This study also showed more than 50% 
reduction of facet loading during full extension after 
implantation. However, the clinical value of this study is 
relatively limited due to a small data sampling and lack 
of clinical investigation in elderly patients with LSS at 
usual lumbar levels. 
Although the exact functional mechanism of pain 
relief is not fully know, it is most likely that by distract-
ing adjacent spinous processes the X STOP device ex-
pands the neural foramina and spinal canal and may 
unbuckle redundant tissue within the canal, such as the 
ligamentum flavum. Although modest, this overall ex-
pansion of the neural and spinal canal diameter may 
decompress the neural structures within. By decom-
pressing these structures the X STOP device is thought 
to alleviate pain associated with NIC. 
insertion loads
LSS is a degenerative process and likewise primarily 
a disease of an older patient population. As a result, 
many candidates for interspinous placement also have 
lower bone mineral density. Placement of the X STOP 
device necessarily requires a degree of lateral loading 
pressure. This loading pressure, however, may place the 
spinous processes at risk. Talwar et al (42) examined ten 
lumbar segments from 4 cadavera. The specimens were 
cleaned and fixed in an axial loading frame. The aver-
age age of the specimens was 64 years. In this study, 
the mean lateral insertion load of the X STOP was 65.6 
N with a range of 10.5 to 150.2 N versus a mean spinous 
process failure load of 316.9 N with a range of 94.7 to 
786.4 N. Although it is evident that the mean lateral 
insertion load during implantation of the X STOP device 
is over 4 times greater than the spinous process failure 
load, it is not without some overlap. Therefore it is con-
ceivable that implantation might pose a risk to some 
patients with particularly brittle spinous processes. Ad-
ditionally, in this same study the authors demonstrate a 
positive correlation between bone mineral density and 
lateral failure load of the spinous process. As a result, 
patients with even mild osteoporosis might not be ideal 
candidates for X STOP placement.
Recently, a novel technique of posterior element 
vertebroplasty to augment the spinous process strength 
has been reported by Idler et al (43). This cadaveric 
study suggests that intraspinous process injection of 
Poly(methyl methacrylate) (PMMA) could increase spi-
nous process strength, reduce the risk of posterior el-
ement fracture, and therefore expand the safety and 
success of implantation for patients with severe osteo-
prosis seeking the X STOP procedure. In vivo practice, 
however, remains to be investigated.
CliniCal data
In May of 2000 a Food and Drug Administration 
investigational trial on the efficacy of X STOP began. 
This study was designed to compare X STOP placement 
versus non-operative (NON OP) treatment for NIC sec-
ondary to LSS.  Nine centers enrolled 200 randomized 
patients in a prospective, controlled trial. A total of 191 
patients were treated with a total of 136 X STOP im-
plantations. Eligible patients were 50 years of age or 
older with leg, buttock, or groin pain, regardless of 
back pain, that could be relieved with flexion. Patients 
were required to be able to sit for 50 minutes without 
pain, already undergone at least 6 months of non-op-
erative therapy, and be able to walk a minimum of 50 
feet. Patients were excluded if they had cauda-equina 
syndrome, previous lumbar surgery at the levels of ste-
nosis, greater than grade I spondylolisthesis, or a fixed 
motor deficit. LSS was confirmed at one or 2 levels on 
CT or MRI. Patients were evaluated to primary outcomes 
using the Zurich Claudication Questionnaire (ZCQ). This 
questionnaire evaluates patient satisfaction, physical 
function, and symptom severity. Treatment qualified as 
a success if the patient was at least “somewhat satis-
fied” and had at least a 0.5 improvement in physical 
function and symptom severity. Patients also completed 
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the Medical Outcomes Study Short Form-36 (SF-36). In 
the X STOP group 64 single level devices and 36 double 
levels were placed. At one year the success of the X STOP 
device was 59% versus 12% in the NON OP group (32). 
Furthermore, X STOP patients also reported significant-
ly higher success rates at 6-week and 6-month follow-
up periods. In a follow-up study of these same patients 
reported at 2 years post treatment, patient satisfaction 
rates were 73.1% in the X STOP group compared to 
35.9% in the NON OP group (44). These results are com-
parable to that of a small study by Lee et al (34) who re-
ported patient satisfaction rates of 70% among X STOP 
implanted patients at a minimum follow-up period of 9 
months. Regarding symptom severity, at 2 years X STOP 
patients reported a 45.4% improvement over baseline 
compared to 7.4% in the NON OP group and physical 
function improvement of 44.3% versus –0.4% in the 
NON OP group (44). Of the 136 X STOP devices placed 
there were no reported intraoperative complications 
and none of the procedures was converted to decom-
pressive surgery at the time of placement. Six patients 
in the X STOP group and 24 patients in the NON OP 
group, however, did eventually undergo decompressive 
surgery at some point during the 2-year period due to 
unresolved stenosis. Three complications were noted 
intraoperatively or within 72 hours postoperatively in-
cluding one ischemic coronary episode, one respiratory 
distress event, and one episode of pulmonary edema. 
Three device related complications were documented 
including an implant dislodgment after a fall, an as-
ymptomatic spinous process fracture discovered on 6 
month follow up imaging, and one patient who com-
plained of worsening pain 382 days after placement of 
the X STOP device. Upon evaluation of all radiographic 
images at 6 weeks and 2 years postoperatively, 96% of 
implanted levels had maintained distraction of the spi-
nous processes (44).
While the results of this study are favorable, crite-
ria for inclusion included at least 6 months of prior con-
servative therapy for LSS. The control or NON OP group 
was then relegated to conservative treatment, a treat-
ment which they have presumably already had limited 
success as evidenced by their ongoing clinical symptoms 
of LSS. The authors also fail to report the SF-36 scores in 
the 2-year follow up study making one- and 2-year fol-
low-up comparison difficult. In a separate study, how-
ever, the mean SF-36 scores from this patient pool are 
reported at 2-year follow. The results from that study 
illustrated that the X STOP group had significantly bet-
ter outcomes than the NON OP group in the domains 
of bodily pain, mental health, physical component sum-
mary, physical functioning, quality of life, role physical, 
and social function (45). Further, the authors point out 
that these SF-36 scores are comparable to published 
outcomes of laminectomy. Yet, of the 200 patients orig-
inally enrolled in the pilot study, only 82 X STOP and 53 
NON OP patients were included in this 2-year follow-up 
study of SF-36 outcomes.
A 4-year follow-up study was also published in July 
of 2006 using the same patient pool from the FDA in-
vestigational trial (46). In this study the Oswestry Dis-
ability Index (ODI) was used to evaluate outcomes at 
an average of 4.2 years postoperatively. Yet only 18 pa-
tients were included in this follow-up study despite ini-
tial enrollment of 200. Of the 18 patients with X STOP 
device placement, the mean preoperative score was 45 
compared to a mean postoperative score of 15 at the 
4-year follow-up (46). The authors qualified device suc-
cess as an improvement of 15 points. Using this criteria, 
14 of 18 patients, or 78%, had successful outcomes (46). 
This study, however, is limited to only 18 patients and 
reports the Oswestry Disability Index, an index not pre-
viously reported in the one or 2-year follow-up studies. 
The study also fails to compare the clinical outcomes to 
those of a control or NON OP group. While the overall 
data from these studies is encouraging, it is limited to a 
maximum of 4.2 years and inconsistent index reporting 
and patient follow up makes comparison and outcome 
determination difficult.
In a separate study, Siddiqui et al (33) enrolled 40 
patients who were surgically treated with the X STOP 
device and examined ZCQ, ODI, and SF-36 scores preop-
eratively and at 3, 6 and 12 month postoperative inter-
vals. At 12 months, 54% of patients reported significant 
symptom improvement, 33% reported improvement in 
physical function, and 71% reported satisfaction with 
the procedure (33). Yet of the 40 enrolled patients in 
this study, 16 were excluded, leaving a study group of 
only 24 patients. Although the results were favorable, 
the outcomes did not show as significant of an improve-
ment as the results from the larger FDA pilot study.
A clinical evaluation study showed X STOP does 
improve pain score and daily function in patients 
with neurogenic claudication, but a good outcome is 
achieved less often than previously reported (47). Com-
plications associated with the X STOP procedure have 
been documented, although available data are limited. 
Negative results of this treatment might be underre-
ported (48). Reported complications include dislocation 
of device, spinous process fracture (49), and foot drop 
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(50). Barbagallo et al (49) consider underlying causes of 
these complications are related to the anatomic vari-
ants of the spinous process and interspinous areas of 
the patients including markedly decreased interspinous 
distance, abnormal shape of the spinous process, and 
facet hypertrophy.
X stoP Versus deComPressiVe surgery
While the X STOP device has been compared to 
non-operative therapy for NIC secondary to LSS in a 
number of studies, there is little data regarding its ef-
fectiveness when compared to lumbar decompression 
surgery. Kondrashov et al (51) compared 18 patients 
who received X STOP implants to 12 patients who un-
derwent laminectomy without fusion. Of the 18 X STOP 
patients, 12 were treated at one level and 6 at 2 levels. 
This compares to 3 of the 12 laminectomy patients who 
were treated at one level and 9 who were treated at 2 
levels. In this study an improvement of 15 Oswestry Dis-
ability Index points defined patient success. Based on 
the success criteria outlined, they concluded that 78% 
of the X STOP group, versus only 33% of the laminec-
tomy group, had successful outcomes at 4 years follow-
up (51). Although this data illustrates a striking contrast 
in success, the pre-operative average ODI scores in the X 
STOP group are 25% greater (45 vs. 36). Previous stud-
ies have demonstrated that patients with more severe 
physical limitation might have better measurable suc-
cess rates than those with less disability (52). Further, 
this is a retrospective analysis and not randomized 
nor double-blinded. The study also included economic 
analysis, comparing direct hospital charges of X STOP 
placement to that of laminectomy without fusion. The 
average direct hospital costs for one level X STOP place-
ment was $15,980 versus a laminectomy average of 
$45,302 for one level. Two level X STOP placement cost 
was $25,618 compared to a 2-level laminectomy cost of 
$46,752 (51). Hospital charges, operative time, and an-
esthesia charges were cited as the main factors under-
lying the greater expense of laminectomy. As already 
discussed, the X STOP device is typically implanted sole-
ly with local anesthetic and patients are normally dis-
charged within 24 hours of surgery. Yet, as the authors 
point out, the analysis only considers the direct hospital 
charges, and a short recovery period after X STOP place-
ment might translate into a substantial additional sav-
ings in indirect costs. 
Recently a clinical investigation by Kutcha and col-
leagues (53) indicated that X STOP implantation in 175 
patients with LSS provided short-term as well as long-
term satisfactory outcome. The Visual Analog Scale 
score of leg pain in the patients was reduced from 6.0 
preoperatively to 3.9 at 6 weeks and 3.9 at 2 years post-
operatively; Oswestry scores were 32.6, 22.7 and 20.3 
respectively. In 8 patients, however, implanted X STOP 
devices had to be explanted with subsequent microsur-
gical decompression due to poor pain control. The au-
thors pointed out that the interspinous device does not 
replace microsurgical decompression in patients with 
massive stenosis and continuous claudication, but of-
fers a safe, effective, and less invasive alternative in se-
lected patients with spinal stenosis (53). Similarly, Nardi 
et al (54) reports another interspinous device, Aperius 
perc LID system offers an easy, safe and effective treat-
ment for patients with lumbar degenerative stenosis 
and neurogenic intermittent claudication which did not 
respond to conservative treatment and this device sys-
tem can represent a valid alternative to the traditional 
surgical techniques However, Asperius perc LID system 
is not available in USA at this time.
other Possible indiCations for X stoP 
imPlantation
Although the X STOP device is approved for NIC 
secondary to LSS, it might lend itself to other applica-
tions. Two studies (55,56) have examined the outcomes 
of X STOP placement for LSS caused by degenerative 
spondylolisthesis. In a study by Anderson et al (55), a 
cohort of 75 patients, 42 treated with X STOP and 33 
treated non-operatively, with spondylolisthesis ranging 
from 5-25% reported a clinical success rate of 63.4% in 
the X STOP group compared to 12.9% in the non-oper-
ative treated patients at 2 years follow-up. This success 
contrasts, however, with a later study by Verhoof and 
colleagues (56) who performed a retrospective chart 
review of 12 consecutive patients who had an average 
spondylolisthesis slippage of 19.6%. In this study, 7 of 
12, or 58%, required decompression with posterolater-
al fusion within 24 months of X STOP placement for de-
generative spondylolisthesis. Furthermore, MRI results 
from this study failed to demonstrate any improvement 
of the axial or sagittal diameter of the central canal af-
ter placement of the X STOP device (56).
As discussed above, the X STOP device is currently 
FDA approved for placement at a maximum of 2 ste-
notic levels. It might, however, offer utility for patients 
with stenosis at multiple levels. Although the device 
might not be independently beneficial in this patient 
population, Fuchs et al (57) have suggested that it could 
possibly be used as an adjunct during decompressive 
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procedures, such as unilateral medial facetectomy for 
the treatment of subarticular stenosis or unilateral to-
tal facetectomy for the treatment of foraminal stenosis. 
The advantage, they argue, is that by decompressing 
neural structures, adjunct X STOP implantation might 
minimize the invasiveness of decompressive surgery by 
lessening the amount of tissue needing to be resected. 
To this end, Fuchs et al (57) prepared 7 cadaveric spines 
in order to investigate the effects of X STOP placement 
on the kinematics of the lumbar spine with graded fac-
etectomy. Results from this study showed that although 
the implant decreased range of motion during flexion 
and extension with graded facetectomy, it did not alter 
axial rotation kinematics (57). The clinical outcome and 
significance of in vivo X STOP placement as an adjunct 
to facetectomy remains to be investigated. 
summary
The X STOP interspinous process distraction de-
vice is a relatively new apparatus approved by the FDA 
for the treatment of mild to moderate LSS resulting 
in NIC. As outlined above, a number of studies, both 
with cadaveric specimens and in vivo, have shown im-
provement in lumbar spinal and neural foraminal di-
mensions after implantation. Furthermore, the above 
investigations into the clinical outcomes of X STOP im-
plantation have thus far yielded encouraging results 
regarding the overall safety and efficacy of this device. 
Nevertheless, the future of the X STOP device in treat-
ing patients with LES and NIC is not yet entirely clear. 
Large, randomized, and truly long-term studies with 
consistent outcome measures and follow up are cur-
rently lacking. As a result, the definitive efficacy and 
safety of this implant still remains debatable. 
ConClusion
Current treatment of LSS with NIC has to this point 
traditionally consisted of either conservative therapy 
or invasive decompressive surgery. The X STOP device 
might offer an intermediately invasive, clinically ben-
eficial, and cost effective third option. 
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